Dexilant

Dexilant is a brand name of dexlansoprazole, approved by the FDA in the following formulation(s):

DEXILANT (dexlansoprazole - capsule, delayed release; oral)

• 
  Manufacturer: TAKEDA PHARMS
  
  Approval date: January 30, 2009
  
  Strength(s): 30MG, 60MG ^[RLD]

Has a generic version of Dexilant been approved?

No. There is currently no therapeutically equivalent version of Dexilant available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Dexilant. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Benzimidazole compound crystal
  Patent 6,462,058
  Issued: October 8, 2002
  Inventor(s): Akira; Fujishima & Isao; Aoki & Keiji; Kamiyama
  Assignee(s): Takeda Chemical Industries, Ltd.
  A novel crystal of (R)-2-[[[3-methyl-4-(2, 2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent.
  
  Patent expiration dates:
  
  
  • June 15, 2020
    
    ✓ 
    Patent use: TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • June 15, 2020
    
    ✓ 
    Patent use: MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • June 15, 2020
    
    ✓ 
    Patent use: HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • December 15, 2020
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Benzimidazole compound crystal
  Patent 6,664,276
  Issued: December 16, 2003
  Inventor(s): Akira; Fujishima & Isao; Aoki & Keiji; Kamiyama
  Assignee(s): Takeda Chemical Industries, Ltd.
  A novel crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent.
  
  Patent expiration dates:
  
  
  • June 15, 2020
    
    ✓ 
    Patent use: MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • June 15, 2020
    
    ✓ 
    Patent use: TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • June 15, 2020
    
    ✓ 
    Patent use: HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • December 15, 2020
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Benzimidazole compound crystal
  Patent 6,939,971
  Issued: September 6, 2005
  Inventor(s): Fujishima; Akira & Aoki; Isao & Kamiyama; Keiji
  Assignee(s): Takeda Pharmaceutical Company, Ltd.
  A novel crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent.
  
  Patent expiration dates:
  
  
  • June 15, 2020
    
    ✓ 
    Patent use: MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
  
  
  
  • June 15, 2020
    
    ✓ 
    Patent use: TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
  
  
  
  • June 15, 2020
    
    ✓ 
    Patent use: HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
  
  
  
  • December 15, 2020
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Process for the crystallization of (R)- or (S)-lansoprazole
  Patent 7,285,668
  Issued: October 23, 2007
  Inventor(s): Hashimoto; Hideo & Urai; Tadashi
  Assignee(s): Takeda Pharmaceutical Company Limited
  The present invention relates to a production method of a crystal of (R)-lansoprazole or (S)-lansoprazole, which includes crystallization at a temperature of about 0° C. to about 35° C. from a C1-4 alkyl acetate solution containing (R)-lansoprazole or (S)-lansoprazole at a concentration of about 0.1 g/mL to about 0.5 g/mL and the like. According to the production method of the present invention, a crystal of (R)-lansoprazole or (S)-lansoprazole superior in preservation stability can be produced efficiently on an industrial large scale.
  
  Patent expiration dates:
  
  
  • June 15, 2020
    
    ✓ 
    Drug substance
  
  
  
  • December 15, 2020
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Controlled release preparation
  Patent 7,790,755
  Issued: September 7, 2010
  Inventor(s): Akiyama; Yohko & Kurasawa; Takashi & Bando; Hiroto & Nagahara; Naoki
  Assignee(s): Takeda Pharmaceutical Company Limited
  A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient.
  
  Patent expiration dates:
  
  
  • August 2, 2026
    
    ✓ 
    Drug product
  
  
  
  • February 2, 2027
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • January 30, 2012 - NEW PRODUCT
  
  
  • July 30, 2012 - PEDIATRIC EXCLUSIVITY
  
  

See also...

• Dexilant Delayed-Release Capsules Consumer Information (Wolters Kluwer)
• Dexilant Consumer Information (Cerner Multum)
• Dexilant Advanced Consumer Information (Micromedex)
• Dexlansoprazole Delayed-Release Capsules Consumer Information (Wolters Kluwer)
• Dexlansoprazole Consumer Information (Cerner Multum)
• Dexlansoprazole Advanced Consumer Information (Micromedex)
• Dexlansoprazole AHFS DI Monographs (ASHP)